Published: 12 July 2017
Author(s): María Dolores García de Lucas, Beatriz Aviles Bueno, Julián Olalla Sierra
Issue: July 2017
Section: Letter to the Editor

Chronic renal failure and albuminuria increase cardiovascular risk in patients with DM2 in proportion to the degree to which they occur and from their earliest stages [1]. At present, only two drugs are known to decrease cardiovascular mortality and provide nephroprotection, namely empagliflozin (analysed in the EMPAREG-OUTCOME study [2]) and liraglutide (according to the LEADER study [3]).


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.